Background: Gene-activated matrix (GAM) induces sustained local production of growth factors to promote tissue regeneration. GAM contains a plasmid DNA (pDNA) encoding target proteins that is physically entrapped within a biodegradable matrix carrier. GAM with a pDNA encoding the first 34 amino acids of parathyroid hormone (PTH 1e34) and a collagen matrix enhances bone regeneration in long bone defects. Demineralized freeze-dried bone allograft (DFDBA) is a widely used osteoinductive bone graft. The present study determined the osteogenic effects of PTH-GAM with a collagen or DFDBA/collagen composite (D/C) matrix for treating craniofacial bone defects. Methods: We constructed a pDNA encoding human PTH 1e34 and performed cyclic AMP ELISA to verify the bioactivity of PTH 1e34. Next, we generated a D/C matrix and PTH-GAMs containing a collagen matrix (PTH-C-GAM) or D/C matrix (PTH-D/C-GAM). Rats with criticalsized calvarial bone defects were divided into four groups, namely, untreated rats (sham group) and rats grafted with D/C matrix, PTH-C-GAM, or PTH-D/C-GAM (D/C, PTH-C-GAM, or PTH-D/C-GAM groups, respectively). PTH expression was determined by performing immunohistochemical staining after 4 and 8 weeks. New bone formation was evaluated by performing radiography, dual-energy X-ray absorptiometry, microcomputed tomography, and histological examination. Results: PTH pDNA-transfected cells secreted bioactive PTH 1e34. Moreover, PTH was expressed at 4 and 8 weeks after the surgery in rats in the PTH-C-GAM group but not in rats in the D/C group. New bone formation in the calvarial bone defects, from more to less, was in the order of PTH-D/C-GAM, PTH-C-GAM, D/C, and sham groups. Conclusion: Our results indicate that PTH-GAM with a collagen matrix promotes local PTH production for at least 8 weeks and bone regeneration in craniofacial bone defect. Moreover, our results indicate that replacement of the collagen matrix with the D/C matrix improves the osteogenic effects of PTH-GAM.
Introduction
Gene-activated matrix (GAM) technology, a non-viral gene therapy strategy, promotes sustained local production of growth factors to enhance tissue regeneration. 1 GAM contains a plasmid DNA (pDNA) encoding target proteins that is physically entrapped within a biodegradable matrix carrier. During the healing process, cells migrate into the matrix, take up the pDNA, and express the encoded proteins. Although the Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
GAM technology is an economic, safe, and simple strategy, the transfection efficiency of GAM is low. Polycations such as polyethylenimine (PEI) have been used to condense pDNA, facilitate its entry into cells, increase gene expression, and enhance the osteogenic effect of GAMs. 2, 3 GAMs with pDNA encoding various osteogenic factors and with different matrices have been studied for promoting bone regeneration. 1,2,4e8 Parathyroid hormone (PTH), a polypeptide containing 84 amino acids (PTH 1e84), regulates blood calcium levels by exerting catabolic effect on bones. Intriguingly, PTH and some PTH fragments exert anabolic effects on bones under certain conditions. 9 PTH 1e34, which contains 34 amino acids of the N-terminus of PTH, exerts anabolic effects on bones.
10,11 PTH 1e34 binds to PTH receptors on osteoblasts and activates several signaling pathways. The anabolic effects of PTH on osteogenic cells are mainly mediated by the activation of cyclic AMP/protein kinase A (cAMP/PKA) signaling pathway. 12 PTH 1e34 greatly enhances bone formation. Systemic PTH 1e34 administration through a low-dose intermittent subcutaneous injection increases bone density in osteoporosis, 13, 14 enhances bone healing, 15 and promotes allograft integration 16 in rats with calvarial bone defects. Local delivery of PTH 1e34 along with an RGD peptide by using a hydrogel matrix exerts beneficial effects on bone defect healing around implants. 17 Local application of PTH 1e34 by using a membrane effectively enhances the healing of 5 mm calvarial bone defect in rats. 18 The GAM technology has been used to deliver PTH 1e34 for promoting bone regeneration in long bone defects. 1, 19, 20 However, the effect of PTH-GAM for treating craniofacial bone defects is still unclear.
Demineralized freeze-dried bone allograft (DFDBA) is one of the most widely used bone grafts in dentistry. DFDBA contains type I collagen, bone morphogenetic proteins (BMP-2, BMP-4, and BMP-7), and other growth factors (including FGF-1 (fibroblast growth factor-1), IGF-1 (insulin-like growth factor-1), TGF-b1 (transforming growth factor-beta1), VEGF (vascular endothelial growth factor) and PDGF (plateletderived growth factor)). 21, 22 The osteoinductive property of DFDBA is attributed to the exposure of its inherent BMPs through demineralization. 23 A DFDBA/collagen composite (D/C) matrix has been used for improving the handling properties of powdered DFDBA. Furthermore, this matrix is more effective than DFDBA 24 or collagen 25 for promoting bone regeneration.
Several studies indicate that PTH 1e34 and BMPs exert synergistic effects for promoting bone regeneration. Combined use of intermittent systemic PTH 1e34 and BMP-2 induces higher bone formation than the use of PTH or BMP alone in a rat model of spinal fusion. 26 Similarly, combined use of intermittent systemic PTH 1e34 and BMP-7 exerted a synergistic effect in a rabbit model of metaphyseal bone healing. 27 Furthermore, intermittent systemic PTH 1e34 treatment improves BMP-2-induced ectopic and orthotopic bone formation. 28 Dual delivery of PTH 1e34 and BMP-4 by using a two-plasmid GAM promotes better bone healing than individual delivery of PTH 1e34 or BMP-4 by using GAM. 19 Local sustained delivery of osteogenic factors through regional gene therapy may enhance bone defect healing with reduced systemic toxicity and prevent the requirement of supraphysiological doses of therapeutic proteins. 1, 29 PTH-GAM encoding PTH 1e34 and with a collagen matrix promotes the healing of long bone defects. 1, 19 Long bones are formed through endochondral ossification, whereas craniofacial bones are formed through intramembranous ossification. Therefore, therapeutic effects of PTH-GAM for treating craniofacial bone defects should be elucidated. We hypothesized that PTH-GAM with a collagen matrix promoted bone regeneration in craniofacial bone defects and that the use of PTH-GAM with a D/C matrix exerted better anabolic effects than PTH-GAM with a collagen matrix. Thus, the present study determined the effects of PTH-GAM with a collagen or D/C matrix in a rat model of critical-sized calvarial bone defects.
Methods

Experimental design and timelines
The study design is shown in Fig. 1 . A gene vector encoding human PTH 1e34 was prepared, and cAMP ELISA was performed to determine the bioactivity of PTH 1e34 secreted by cells transfected with this vector. Materials for implantation into the rat model of calvarial bone defects, including D/C matrix, PTH-GAM with a collagen matrix (PTH-C-GAM), and PTH-GAM with a D/C matrix (PTH-D/C-GAM), were prepared. The structure of PTH-C-GAM was examined by performing scanning electron microscopy (SEM). Rats with critical-sized calvarial bone defects were divided into four groups, namely, untreated rats (Sham group) and rats grafted with D/C, PTH-C-GAM, and PTH-D/C-GAM (D/C, PTH-C-GAM, and PTH-D/C-GAM groups, respectively). Endpoint analyses were performed after 4 and 8 weeks. PTH expression was determined by performing immunohistochemical staining, and bone regeneration was evaluated by performing radiography, dual-energy X-ray absorptiometry (DEXA), microcomputed tomography (mCT), and histological examination (H&E staining). 
Preparation of pDNA carrying the human PTH gene (pUMVC1/hPTH)
The human PTH1e34 gene (prepro-PTH 1e34) 19 was inserted into a plasmid (pUMVC1) with a CMV promotor to generate pUMVC1/hPTH pDNA. pUMVC1/LacZ was used as a negative control for cAMP ELISA. Endotoxin-free plasmids were prepared using EndoFree plasmid Giga-prep kit (Qiagen, CA, USA).
Cyclic AMP ELISA
cAMP ELISA was performed to verify the bioactivity of cell-secreted PTH 1e34 because cAMP is a downstream effector of PTH.
30 HEK293 cells were transfected with pUMVC1/hPTH or pUMVC1/LacZ pDNA by using a transfection reagent (FuGENE 6 transfection reagent; Roche, IN, USA). UMR-106 cells express PTH receptors and show the activation of the cAMP/PKA pathway after PTH stimulation. 31 In the present study, UMR-106 cells, which were pretreated with isobutylmethylxanthine to block phosphodiesterase activity, were treated with a conditioned medium obtained by culturing transfected HEK293 cells for 10 min at 37 C. cAMP in the lysate of UMR-106 cells was measured using cAMP ELISA kit (cAMP ELISA Biotrak kit; Amersham Biosciences, NJ, USA).
Preparation of DFDBA
The hind limb bones of 8-week-old male SpragueeDawley (SD) rats were collected and ground in liquid nitrogen. Bone particles with a size of 250e500 mm were collected using sieves and were used in this study. Bone particles was demineralized using 0.5 N sterile HCl, washed by rocking in anhydrous alcohol at 4 C, and rinsed with sterile distilled water. Completeness of demineralization was confirmed by performing radiography (50 kVp and 0.02 s). Next, the bone particles were freeze-dried and were stored at À80 C for further use.
Preparation of D/C matrix, PTH-C-GAM, and PTH-D/C-GAM
pUMVC1/hPTH pDNA and branched 25 kDa PEI (SigmaeAldrich, MO, USA) 32 were mixed at a nitrogen/phosphate molar ratio of 9 and DNA/PEI molecular weight ratio of 1:1.25. The mixture was kept at room temperature for 30 min and at À80 C for 12 h and was lyophilized under vacuum at 100 mT and À45
C for 24 h. Rat type I atelocollagen was prepared as described previously. 33 Next, PEI-pUMVC1/ hPTH pDNA (200 mg pDNA) mixture, atelocollagen (2%), and/or DFDBA (collagen/DFDBA ratio, 20:80) were mixed; placed in round Teflon molds (8 mm diameter and 4 mm height); frozen at À80 C; and freeze-dried to form spongelike PTH-D/C-GAM and PTH-C-GAM. D/C matrix was prepared in the same manner but without adding the PEIpUMVC1/hPTH pDNA mixture. Next, the sponge-like matrices were crosslinked using 25% glutaraldehyde vapor for 4 h at 37 C. The remaining aldehyde groups were removed using 0.1 M glycine, and the matrices were rinsed three times with sterile PBS. Finally, PTH-D/C-GAM, PTH-C-GAM, and D/C matrix were sterilized with 70% ethanol and were freeze-dried before use.
Scanning electron microscopy
PTH-C-GAM was gold coated in an ion sputter (E101 ion sputter ® ; Hitachi, Japan) and was observed under a scanning electron microscope (S-2700; Hitachi).
Rat model of calvarial bone defect
Protocols for performing animal experiments were approved by the Animal Research Committee of the National Yang-Ming University. The study included 42 male SD rats (age, 4 weeks) that were randomly divided into four groups, namely, Sham, D/C, PTH-C-GAM, and PTH-D/C-GAM groups, and were examined at two time points, i.e., 4 and 8 weeks. At each time point, the Sham group and the other three groups used 3 and 6 rats per group, respectively. The rats were anesthetized by intraperitoneally injecting a mixture of xylazine and ketamine hydrochloride (mixed in 1e4 ratio, 0.17 ml mixture per 100 g body weight). Criticalsized (8 mm diameter) calvarial bone defects were created using a trephine bur under saline irrigation. 34 The defects were not treated (Sham) or grafted with materials (D/C composite matrix, PTH-C-GAM, or PTH-D/C-GAM). Rat calvarias were collected after 4 and 8 weeks for endpoint analyses.
Radiograph evaluation
Radiographs of the rat calvarias were obtained (50 kVp, 8 mA, and 10 s) along with those of an acrylic step wedge containing ten 2.7 mm-thick steps. The step wedge was used as a reference to correct density variation caused by film exposure and processing. Images on the developed films were scanned and digitalized, and average bone density within the calvarial defects was quantified using an image analysis software (ImageQuant, Version 5.2; Molecular Dynamics, CA, USA). Results are presented as acrylic thickness (mm).
Dual energy X-ray absorptiometry
Bone mineral content (BMC) and new bone area in the rat model of calvarial bone defects were measured using a DEXA system designed for small animal research (pDEXA Sabre; Norland Medical Systems, WI, USA). Scanning parameters used were width, 1 cm; length, 1 cm; speed, 5 mm/s; and resolution 0.5 Â 0.5. DEXA measurements were analyzed using a software (version 3.9.4) provided in the DEXA system. Original defect area was set as the region of interest for all the measurements.
Microcomputed tomography
Rat calvarias were scanned using a compact mCT imaging system (SkyScan 1174; SkyScan, Belgium). Scans were acquired at 8.6 mm image pixel size, 48 kVp, and 120 mA. Next, threedimensional (3D) reconstruction of the images and bone volume analysis of the defect zone (8 mm) were performed using SkyScan's volumetric reconstruction software (NRecon) by using a threshold of 45. This program uses a modified Feldkamp algorithm with an automatic adaptation to scan geometry.
Immunohistochemical staining and histological examination
Rat calvarias were fixed in 4% formaldehyde, decalcified, embedded in paraffin, and sectioned perpendicular to the sagittal suture at the center of the created defect. PTH expression was determined by performing immunohistochemical staining with a monoclonal mouse anti-human PTH antibody (T-9912; dilution, 1/200; BMA Biomedicals, Switzerland) and horseradish peroxidase-conjugated goat antimouse IgG (NEF822; dilution, 1/500; PerkinElmer, MA, USA). PTH was visualized using an 3-amino-9-ethylcarbazole (AEC) chromogen. Nuclear counterstaining was performed using hematoxylin. For histological examination, the tissues sections were stained with hematoxylin and eosin and were observed under a light microscope.
Statistical analysis
Results are presented as mean ± standard deviation. Statistical comparisons were performed using one-way ANOVA with GraphPad Instat 6.0c (GraphPad Software, CA, USA). Differences between the groups were considered significant at p < 0.05.
Results
Establishment of pUMVC1/hPTH and validation of human PTH 1e34 bioactivity
To verify the bioactivity of PTH 1e34 secreted by cells transfected with the pUMVC1/hPTH pDNA, conditioned medium of HEK293 cells transfected with pUMVC1/hPTH or pUMVC1/LacZ was collected and was used for treating UMR-106 cells. Lysates of UMR-106 cells in the pUMVC1/hPTH group showed significantly higher cAMP levels than those of UMR-106 cells in the Sham and pUMVC1/LacZ negative control groups (Fig. 2) . These results indicate that cells secret bioactive PTH 1e34 after taking up the pUMVC1/hPTH plasmid.
Morphology of PTH-C-GAM
Morphology of PTH-C-GAM was examined by performing SEM (Fig. 3) . SEM images showed that PTH-C-GAM had high porosity, with different-sized pores (ranging from tens to hundreds of microns), and good interpore connectivity.
Sustained expression of human PTH 1e34 in the rat model of calvarial bone defects
In the present study, we used GAMs to promote sustained local administration of PTH. We determined the local expression of PTH at 4 and 8 weeks after PTH-C-GAM implantation by performing immunohistochemical staining (Fig. 4) . We observed that rats in the PTH-C-GAM group showed stronger PTH expression at both the time points than rats in the D/C group. These results indicate that local cells take up the pUMVC1/hPTH pDNA and effectively secret PTH for at least 8 weeks.
PTH-GAMs increase bone mineral density, bone mineral content, new bone area, and bone volume
To clarify whether local delivery of PTH by using PTHGAMs promoted the healing of calvarial bone defects, we performed endpoint analysis with radiography, DEXA, and mCT. Radiography data indicated that rats in the Sham group showed minimal new bone formation at 4 and 8 weeks. Rats in all the other groups showed higher bone growth than those in the Sham group (Fig. 5A) . Relative bone density was the highest in rats in the PTH-D/C-GAM group, followed by that in rats in the PTH-C-GAM, D/C, and Sham groups in the given order (Fig. 5B) .
DEXA was performed to determine BMC and new bone area. Rats in the PTH-D/C-GAM group showed higher BMC than rats in the D/C and PTH-C-GAM groups at both 4 and 8 weeks (Fig. 5C ). Similar trend was observed for new bone area (Fig. 5D) . At 8 weeks after the implantation, rats in the PTH-D/C-GAM group showed 6.15-, 3.34-, and 1.27-fold larger new bone area than rats in the Sham, D/C, and PTH-C-GAM groups, respectively (Fig. 5D) .
Next, we performed mCT analysis, including 3D reconstruction of images and measurement of bone volume. Results obtained from the 3D reconstruction of mCT images indicated that rats in the Sham group showed the lowest new bone formation compared with rats in the other groups at 4 and 8 weeks. Rats in the PTH-D/C-GAM group showed the highest bone regeneration effect (Fig. 5E ). In addition, rats in the PTH-D/C-GAM group showed 7.02-, 4.26-, and 1.47-fold higher bone volume than rats in the Sham, D/C, and PTH-C-GAM groups, respectively, at 8 week after the implantation (Fig. 5F) .
Together, these results indicate that PTH-D/C-GAM followed by PTH-C-GAM and D/C matrix have the best bone regeneration potential.
Histological examination showed enhanced new bone formation
H&E staining of tissue sections was performed to examine new bone formation in sites showing calvarial bone defects. Rats in the Sham group showed thin regenerative tissues, with minimal bone formation ( Fig. 6a and e) . Apparent new bone formation characterized by thick regenerative tissues and increased new bone volume was observed in rats in the D/C, PTH-C-GAM, and PTH-D/C-GAM groups at 4 weeks after the implantation (Fig. 6bed) . In addition, rats in the PTH-D/ C-GAM group (Fig. 6d) showed more compact and mature morphology of the new bone tissue than those in the D/C and PTH-C-GAM groups (Fig. 6b and c) . At 8 weeks after the implantation, rats in the D/C and PTH-C-GAM groups showed loose morphology of the new bone tissue (Fig. 6f and g ), whereas those in the PTH-D/C-GAM group showed the most mature morphology of the new bone tissue within criticalsized calvarial bone defects (Fig. 6h) .
Discussion
Local PTH 1e34 administration by using GAM enhances the healing of long bones. Results of the present study indicate that application of PTH-GAM promotes bone regeneration in craniofacial bone defects. In addition, change in the carrier matrix of PTH-GAM from collagen to D/C matrix further increases its osteogenic effect.
The osteoinductive capacity of commercial DFDBA is usually not verified by tissue banks. Many factors may contribute to the differences in the osteoinductive effect of DFDBA, such as different processing protocols and donor age. 35, 36 Variation in the osteoinductive properties of purchased DFDBA may significantly affect its regenerative potential. 37 Therefore, the DFDBA used in this study was prepared and confirmed for the presence of osteoinductive effect via a subcutaneous ectopic bone formation method.
GAM promotes sustained local production of pDNAencoded growth factors. Results of immunohistochemical staining performed at 8 weeks after PTH-C-GAM implantation showed that local cells took up the pDNA present in PTH-C-GAM and secreted PTH for at least 8 weeks (Fig. 4) . These results are consistent with those from previous studies, which showed that the combination of GAM and PEI promotes the expression of encoded proteins up to 15 weeks. 2, 7 Bone regenerative effect was the highest in rats in the PTH-D/C-GAM, followed by that in rats in the PTH-C-GAM, D/C, and Sham groups in the given order. First, rats in the D/C group showed better new bone formation than rats in the sham group, which was consistent with that observed in previous studies that showed the beneficial effect of the D/C matrix. 24, 25 Second, PTH-D/C-GAM and PTH-C-GAM showed higher osteogenic potential than the D/C matrix, thus supporting the high bone regeneration potential of PTH-GAMs. Third, the difference between PTH-D/C-GAM and PTH-C-GAM may be due to the synergistic effect of PTH and BMP reported previously. 19,26e28 Effects of PTH on bones depend on the mode of delivery. Intermittent PTH administration through subcutaneous injection induces anabolic effects.
14e16 Continuous PTH administration increases osteoclastic bone resorption. 38, 39 Local PTH production by using GAMs does not seem to be intermittent. Further studies are needed to elucidate mechanisms underlying the anabolic effects induced by PTH-GAMs on bones.
Use of recombinant proteins such as PDGF-BB 40 and BMP-2 41 in regenerative therapies is simple and feasible. However, these proteins are associated with limitations such as high cost, short half-life, and difficulties in sustained local delivery. 42 The use of GAMs can overcome many limitations associated with the direct administration of proteins. 43 The results of the present study indicate that combined use of the D/C matrix and PEI-condensed pDNA encoding PTH 1e34 has a high potential for treating difficult-to-heal large craniofacial bone defects. The methods and results presented here will be of value for using PTH-GAMs for promoting craniofacial bone regeneration in the future. 
